Insights

At Inbeeo, Market Access truly is our passion and we love to share our thoughts on the latest developments in the field through our blog and also in publications. Should you have a topic that you would value our thoughts on then please do get in touch – we would love to hear from you.

The Inbeeo Market Access Consulting Team

Team Inbeeo Ready For ISPOR Europe 2022 in Vienna

Sara, John, Konstantina and Yigit look forward to meeting like-minded market access and HEOR professionals around our poster presentations or a cup of coffee. Please message the team or fill

Four Market Access Measures Triggered By COVID-19 That Are Here To Stay

Four Market Access Measures Triggered by COVID-19 That Are Here To Stay

Many market access decisions were intended to provide rapid one-off answers to one of the most extraordinary situations healthcare systems have ever had to face, but some of them are telling us something about the more profound changes that are likely to affect pharmaceutical market access in the longer run.

ASMR Ratings Given to New Products in France since 2008

In France, the value equation may change (a little)

France’s healthcare industry strategic council CSIS met an agreement with the French Government to strengthen France’s appeal for HealthCare industries. Inbeeo dives in to investigate the impact on market access and pricing.

The Six Drugs that on Average Cost Patients over $10,000 a Year

Six Drugs that Cost a Medicare Part D Beneficiary more than $10,000 a Year

No one will argue that Medicare Part D met a genuine need at its inception in the mid-2000s – offering Medicare beneficiaries an affordable voluntary health insurance plan that would cover their outpatient prescription needs. Fast forward 10 years. Has Part D met its objective? In terms of the availability of a wide range of plans at an affordable premium in all parts of the nation, yes, definitely. In terms of actual payments made to beneficiaries, this is a question mark.